Neuroretinal damage associated with pituitary macroadenoma: endocrine and radiological predictors and correlation with optical coherence tomography-derived biomarkers - Scorecard - MDSpire
Advertisement
Neuroretinal damage associated with pituitary macroadenoma: endocrine and radiological predictors and correlation with optical coherence tomography-derived biomarkers
Clinical Scorecard: Association of Neuroretinal Injury with Pituitary Macroadenoma: Endocrine and Imaging Predictors and Their Relationship with Optical Coherence Tomography Biomarkers
At a Glance
Category
Detail
Condition
Pituitary Macroadenoma
Key Mechanisms
Endocrine dysfunction and visual pathway compression due to tumor growth.
Target Population
Adults aged 18-80 years diagnosed with pituitary macroadenoma.
Care Setting
Endocrinology, Neurosurgery, Radiology, and Ophthalmology departments.
Key Highlights
Larger tumor volumes correlate with worse visual field outcomes.
OCT detects early visual pathway damage better than visual acuity.
Hormonal normalization occurs post-surgery for ACTH, cortisol, IGF-1, and prolactin.
Guideline-Based Recommendations
Diagnosis
Utilize OCT and perimetry for assessing visual pathway integrity.
Management
Surgical intervention is indicated for decompression in cases of significant visual impairment.
Monitoring & Follow-up
Regular follow-up with OCT to monitor retinal changes post-surgery.
Risks
Risk of visual impairment increases with larger tumor size and longer disease duration.
Patient & Prescribing Data
40 patients with pituitary macroadenoma.
Surgery improves hormonal profiles and may stabilize visual function.
Clinical Best Practices
Early detection of visual pathway involvement is critical for timely intervention.
Assess hormonal profiles alongside imaging studies for comprehensive management.
Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.
